The Flatley family has had a long standing commitment to the fight against cystic fibrosis (CF). In 2009, recognizing that funding for drug discovery was scarce, and the need for new therapies ever more urgent, John Flatley and Richard Fitzpatrick founded the Flatley Discovery Lab (FDL) in August, 2009 as a not-for-profit company with the sole focus of discovering small molecule modulators of CFTR (cystic fibrosis transmembrane conductance receptor) and bringing them to patients. With modulators emerging as a promising class of new therapies for CF, the lab sought to amplify these efforts with a major effort to identify additional drugs to restore CFTR activity. FDL’s high throughput screening lab has screened more than 1 million compounds and 50,000 compound combinations leading to the identification of several novel chemical series and development of a robust pipeline of CFTR modulators. In September 2015, FDL achieved the milestone of initiating its first human clinical trial with FDL169, and currently two CFTR modulators are advancing in human clinical trials. The Flatley family and FDL maintain their dedication to that original vision–to develop new medicines for the benefit of CF patients.
On behalf of everyone at FDL,
Richard J. Fitzpatrick, PhD, MBA
Chief Executive Officer